During the corresponding time, Nektar Therapeutics saw a revenue deteriorated by -9.34 % year on year, sequentially revenue fell by -6.72 %. While revenue at the Nektar Therapeutics's corporate clients
Sources:
Nektar Therapeutics’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Nektar Therapeutics’s corporate clients.
For your research, we’ve provided 9 tables on Nektar Therapeutics corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.